Minsheng Health: Announcement on the progress of the second phase of repurchasing the company's shares through centralized bidding transactions

Securities code: 301507 Securities abbreviation: Minsheng Health Announcement number: 2026-001

Hangzhou Minsheng Health Pharmaceutical Co., Ltd.

Regarding the second phase of repurchasing the company’s shares through centralized bidding transactions

Progress Announcement

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete and does not contain any false records, misleading statements or major omissions.

Important content reminder:

Implementation of the second phase of the repurchase plan: As of December 31, 2025, Hangzhou Minsheng Health Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has repurchased a total of 996,900 shares through a special securities account for repurchase and centralized bidding transactions, accounting for 0.28% of the current company's total share capital. The highest transaction price is 15.67 yuan/share, and the lowest transaction price is 14.39 Yuan/share, the payment amount is 14,999,327.00 yuan (excluding transaction fees).

1. Basic information on share repurchase

The company held the 11th meeting of the second board of directors on October 28, 2025, and reviewed and approved the "Proposal on the Second Phase of Repurchasing the Company's Shares through Centralized Bidding Transactions", and agreed that the company would use its own funds to implement the second phase of the company's share repurchase through centralized bidding transactions for equity incentives. The repurchase price shall not exceed 150% of the average trading price of the company's shares in the thirty trading days before the company's board of directors considers and approves the resolution to repurchase shares, which is RMB 21.06 per share; the number of shares to be repurchased is expected to be 2.1 million-2.4 million shares, and the total amount of repurchase funds is expected to not exceed RMB 50.544 million, subject to the actual repurchase situation; the implementation period of this repurchase of the company's shares is within 12 months from the date of the board of directors' approval of the repurchase plan.

For details, please refer to the "Announcement on the Second Phase Plan to Repurchase the Company's Shares through Centralized Bidding Transactions" (Announcement No.: 2025-051) and the "Repurchase Report (Second Phase)" (Announcement No.: 2025-054) disclosed by the company on the cninfo.com (www.cninfo.com.cn) on October 30, 2025, and November 5, 2025.

2. Progress of the company’s implementation of the repurchase plan

According to the "Share Repurchase Rules of Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 9 - Repurchase of Shares" and other relevant regulations, during the repurchase period, the company should disclose the repurchase progress as of the end of the previous month on the first three trading days of each month. The progress of the company’s second phase of share repurchase is now announced as follows:

As of December 31, 2025, the company has repurchased a total of 996,900 shares through a special securities account and centralized bidding transactions, accounting for 0.28% of the current total share capital of the company. The highest transaction price is 15.67 yuan/share, the lowest transaction price is 14.39 yuan/share, and the payment amount is 14,999,327.00 yuan (excluding transaction fees).

This share repurchase complies with relevant laws and regulations and the company's established share repurchase plan.

3. Other matters

(1) The time for the company to repurchase shares, the price of the shares to be repurchased, the number of shares to be repurchased, and the entrustment period for centralized bidding transactions, etc. are in compliance with the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 9 - Share Repurchase" and the relevant provisions of the company's share repurchase plan, as detailed below:

1. The company did not repurchase the company’s shares during the following periods:

(1) From the date when a major event that may have a significant impact on the trading price of the company's securities and its derivatives occurs or during the decision-making process to the date of disclosure in accordance with the law;

(2) Other circumstances specified by the China Securities Regulatory Commission and Shenzhen Stock Exchange.

2. The company repurchases shares through centralized bidding transactions and meets the following requirements:

(1) The entrusted price shall not be the price that limits the trading increase of the company’s stock on that day;

(2) No share repurchase entrustment shall be made during the opening call auction, closing call auction and trading days when the stock price has no limit on the price increase or decrease of the Shenzhen Stock Exchange;

(3) Other requirements stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange.

(2) The company will continue to implement this repurchase plan within the repurchase period based on market conditions, and perform its information disclosure obligations in a timely manner in accordance with relevant laws, regulations and normative documents. Investors are kindly requested to pay attention to investment risks.

Announcement is hereby made.

Board of Directors of Hangzhou Minsheng Health Pharmaceutical Co., Ltd. January 7, 2026